Enzaplatovir

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameEnzaplatovir
Drug Alias NameBTA-585BTA-C585
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionViral fusion proteins inhibitors
TargetsViral fusion proteins
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAviragen Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAviragen Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsRespiratory Syncytial Virus Infections

Other Information

ATC CodeN/A
Related LinksN/A